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Summary
BACKGROUND: Although sentinel lymph node biopsy
(SLNB) is the most sensitive and accurate investigative
modality for establishing regional node status in patients
with melanoma, its role and benefit in melanoma of differ-
ent Breslow’s thickness is still controversial.
OBJECTIVE: The current study aimed mainly to evaluate
the effects of SLNB results on important outcome paramet-
ers in primary melanomas with different Breslow’s thick-
nesses.
METHODS: In a retrospective cohort (1990 to 2014), all
cases of single, primary localised cutaneous melanoma tu-
mours were evaluated. Data collected consisted of tumour
location, tumour type, ulceration, Breslow’s thickness and
SLNB result. In addition, locoregional recurrence, distant
metastases, disease-free and overall survival were used as
the important parameters to compare outcome among the
various groups in the current study.
RESULTS: A total of 1111 patients (527 female, 584 male;
mean age 64.33 ± 15.44 years) were considered in the ana-
lyses in this study, with mean follow-up of 22 77.3 days.
The multivariate Cox analysis showed that age, ulcera-
tion, Breslow’s depth and SLNB result significantly de-
creased disease-free survival. This analysis also demon-
strated that age, gender, ulceration, Breslow’s depth and
SLNB result significantly affected overall survival. Fur-
thermore, the Kaplan-Meier method showed that the pa-
tients with negative SLNB had longer disease-free survival
than the patients with positive SLNB in thin, intermediate
and thick melanomas (p <0.001, p <0.001 and p = 0.008,
respectively). Additionally, in the patients with intermedi-
ate melanomas significant better overall survival outcome
was observed in those with negative SLNB (p <0.001).
Despite worse mean overall survival of the patients with
thin or thick melanomas and positive SLNB compared with
the patients with negative SLNB, this difference was not
statistically significant (p = 0.077 and p = 0.13, respect-
ively).
CONCLUSION: Sentinel lymph node biopsy of melan-
omas provides important prognostic information and the
outcome provides additional information for the manage-
ment and treatment of the patient.
Key words: Breslow’s thickness; melanoma; outcome;
sentinel lymph node biopsy
Introduction
Malignant melanoma is a common type of skin cancer,
which is potentially lethal if not diagnosed and excised
at an early stage [1–3]. Although mortality rates have in-
creased at a significantly lower rate, which has been at-
tributed to improved early detection as evidenced by the
diagnosis of thinner lesions over this time period [4, 5],
its incidence continues to increase fastest of all cancers in
Switzerland [6]. Since there is such a high incidence rate of
melanoma, population-based data are important to improve
early diagnosis and streamline screening programmes in
local populations [3]. It is estimated that approximately 15
to 25% of patients with a clinically negative lymph node
examination carry microscopic nodal metastases. As a res-
ult, sentinel lymph node biopsy (SLNB), which is the most
sensitive and accurate investigative method for establishing
regional node status in patients with melanoma, has gained
rapid acceptance in the treatment of patients with melan-
oma [7–11]. However, its role and benefit in patients with
melanomas of different Breslow’s thickness is still contro-
versial [12]. As a result, the current study mainly aimed to
evaluate the effect of lymph node biopsy results on disease-
free and overall survival of patients with melanomas of dif-
ferent Breslow’s thickness.
Materials and methods
We performed a retrospective cohort review of the melan-
oma database of patients from the University Hospital
Bern, Switzerland. The study period was from 1990 to
2014, with the follow-up ending in 2015. All cases of
single, primary localised cutaneous melanoma tumours
were evaluated. Patients without complete medical records,
documented surgical margins or regular follow-up were ex-
cluded from the study. All procedures were carried out in
accordance with the standards of the ethical committee of
the Canton of Bern, Switzerland (2016-00382), on human
experimentation and with the Helsinki Declaration of 1975,
as revised in 1983. Collected data consisted of patients’
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gender, age, tumour location, tumour type, Breslow’s thick-
ness, ulceration and SLNB result. In addition, locoregional
recurrence, distant metastases, disease-free and overall sur-
vival were used as the crucial parameters to compare out-
come between the study groups.
In this study, the lesions were categorised into thin (≤1.0
mm), Intermediate (1.0–4.0 mm) and thick melanomas
(≥4.0 mm) [13]. Additionally, locoregional recurrence after
primary excision was considered to include recurrence loc-
ally at the site of the primary lesion, regionally in the
draining lymph node basin, and/or anywhere in between
[11, 14–16]. Spread from primary tumour to distant lymph
nodes or distant organs was defined as distant metastasis
[17–19].
Statistical analysis
All analyses were conducted using SPSS version 21.0
(IBM, Armonk, NY, U.S.A.). All p-values relate to a two-
sided test with an α level of 0.05. For categorical and con-
tinuous characteristics, χ2-test, Fisher’s exact test and ana-
lysis of variance (ANOVA) were used to detect possible
differences among the study groups. Disease-free and over-
all survival were estimated using the Kaplan-Meier meth-
od. For disease-free survival, patients confirmed to be
without locoregional recurrence or distant metastasis were
censored using their last contact date. For overall survival,
patients confirmed to be alive were censored using their
last contact date. The confidence interval (CI) of hazard
ratios (HRs) for Cox regression and overall survival (for
time-to-event variables) were calculated. The p-value
based on log rank (Mantel-Cox test) was used to check if
the study groups had different disease-free and overall sur-
vival functions. The Cox proportional hazard model was
used to estimate the bivariate association between each
endpoint and the available patient/tumour characteristics.
Prognostic factors considered for the multivariate Cox ana-
lysis of the primary melanomas were age, gender, tumour
thickness, ulceration and positive SLNB [9, 20, 21]. A p-
value<0.05 was considered statistically significant.
Results
Patient and tumour characteristics
Between 1990 and 2014, 1111 patients (527 female, 584
male; mean age 64.33 ± 15.44 years) with single, primary
localised cutaneous melanoma tumours were considered in
Figure 1
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free
and overall survival in thin melanoma (p <0.001 and p = 0.077,
respectively).
the analyses in this study, with mean follow-up of 22 77.3
days.
The mean ± standard deviation (SD) Breslow’s depth of the
study patients’ primary melanoma tumours was 1.92 ± 2.70
mm (0.09–45 mm). A total of 179 (16.1%) of our study pa-
tients had ulceration in their tumours. Superficial spreading
melanoma was the most frequent (48.6%) and amelanot-
ic melanoma the least frequent (0.5%) tumour type. Fur-
thermore, the trunk area was the location of the highest
number of primary tumours (40.0%). For 889 (80.0%) pa-
tients, SLNB was performed. Of the melanomas evaluated,
464 (41.8%) were thin, 523 (47.0%) intermediate and 124
(11.2%) thick. As presented in table 1, statistical analysis
showed no significant differences between the patients in
the different thickness groups regarding age, gender and
melanoma location. However, the incidence of ulceration,
positive sentinel lymph node biopsies, metastasis and death
increased significantly with the thick melanomas (p
<0.001). Furthermore, the multivariate Cox analysis
showed that age, ulceration, Breslow’s depth and SLNB
result significantly influenced disease-free survival. This
analysis also showed that age, gender, ulceration,
Breslow’s depth and SLNB result significantly affected
overall survival (table 2).
The prognostic value of sentinel lymph node biopsy in
patients with thin melanomas
Ten (2.2%) patients with thin melanoma had locoregional
recurrence and 15 (3.2%) had distant metastases, which
were significantly more frequent in the patients with pos-
itive SLNB (p = 0.007 and p = 0.003; respectively).
However, although the death attributed to melanoma was
more frequent in the patients with positive SLNB, this dif-
ference was not statistically significant (p = 0.187; tables
1 and 3). Furthermore, Kaplan-Meier methods showed that
the patients with negative SLNB had better disease-free
survival than the patients with positive SLNB (p<0.001).
Although mean overall survival time of the patients with
positive SLNB (11.92 years, 95% CI 10.14–13.71) was less
than in the patients with negative SLNB (23.45 years, 95%
CI 23.06–23.84), this difference was not significant (p = 0.
077; table 4, fig. 1).
The prognostic value of sentinel lymph node biopsy in
patients with intermediate melanomas
Locoregional recurrence, distant metastases and death at-
tributed to melanoma occurred in 74 (14.1%), 69 (13.2%)
Figure 2
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free
and overall survival in intermediate melanoma (p <0.001 and p
<0.001, respectively).
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and 51 (9.8%), respectively, among the patients with inter-
mediate melanomas, and were significantly more frequent
in the patient with positive SLNB (p <0.001; tables 1 and
3). Additionally, Kaplan-Meier survival analysis showed
significantly better disease-free and overall survival in the
patients with negative SLNB than in the patients with pos-
itive SLNB (p <0.001; table 4, fig. 2).
The prognostic value of sentinel lymph node biopsy in
patients with thick melanomas
Evaluation of thick melanomas showed 41 (33.1%) patients
with locoregional recurrence, 41 (33.1%) with distant
metastases and 29 (23.4%) with death attributed to melan-
oma, which were significantly more frequent in the patients
with positive SLNB (p = 0.001, 0.017 and 0.05; respect-
Figure 3
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free
and overall survival in thick melanoma (p = 0.008 and p = 0.13,
respectively).
ively; tables 1 and 3). In addition, Kaplan-Meier survival
analysis showed significantly better disease-free survival in
the patients with negative SLNB than in the patients with
positive SLNB (p = 0.008). However, despite worse mean
overall survival in the patients with positive SLNB (10.10
years, 95% CI 8.16–12.03) compared with the patients with
negative SLNB (12.91 years, 95% CI 11.30–14.52), this
difference was not statistically significant (p = 0.13; table
4, fig. 3).
Discussion
The use of SLNB for accurate disease staging is a key part
of the early detection of occult metastatic disease in the
regional lymph nodes and the preliminary management of
many people with localised melanoma [22–25]. However,
it is not uniformly accepted at all specialised centres as the
standard of care as a result of the important controversy
relating to its usefulness (therapeutic efficacy, safety and
costs) [22, 25]. However, our study on different melanoma
groups indicated that a positive SLNB is associated with
worse outcomes in melanoma patients, regardless of
melanoma thickness. In this study, multivariate Cox ana-
lysis found that age, ulceration, Breslow’s depth and SLNB
result significantly decreased disease-free survival. Others
have also reported the impact of SLNB status [12, 26–28],
ulceration [12, 26, 27], and increased Breslow’s thickness
[12, 28, 29] on disease-free survival. This analysis also
demonstrated that age, gender, ulceration, Breslow’s depth
Table 1: Patients and tumour characteristics according to melanoma thickness.
Melanoma groupCharacteristics
Thin Intermediate Thick
p-value
Female 225 (48.5) 254 (48.6) 48 (38.7)Gender (no./%)
Male 239 (51.5) 269 (51.4) 76 (61.3)
0.119
Mean ± SD 64.0 ± 15.3 64.6 ± 15.7 64.1 ± 14.6Age
(Years) Median 64.0 66.0 67.0
0.819
Mean ± SD 0.6 ± 0.2 1.9 ± 0.8 6.9 ± 5.6Breslow
(mm) Median 0.6 1.6 5.2
–
Head and Neck 67(14.4) 65 (12.4) 27 (21.8)
Trunk 196 (42.2) 200 (38.2) 48 (38.7)
Upper Extremity 73 (15.7) 104 (19.9) 15 (12.1)
Melanoma site (no./%)
Lower Extremity 128 (27.6) 154 (29.4) 34 (27.4)
0.059
NM 48 (10.3) 246 (47.0) 89 (71.8)
SSM 329 (70.9) 193 (36.9) 18 (14.5)
Melanoma Type
(no./%)
Others 87 (18.8) 84 (16.1) 17 (13.7)
<0.001
Ulceration 14 (3.0) 107 (20.5) 58 (46.8) <0.001
Positive SLNB 14 (5.0) 95 (19.3) 47 (38.8) <0.001
Locoregional recurrence 10 (2.2) 74 (14.1) 41 (33.1) <0.001
Distant metastases 15 (3.2) 69 (13.2) 41 (33.1) <0.001
Death attributed to melanoma 11 (2.4) 51 (9.8) 29 (23.4) <0.001
NM = nodular melanoma; SD = standard deviation; SLNB = sentinel lymph node biopsy; SSM = superficial spreading melanoma
Table 2: Cox analysis based on melanoma thickness.
Factors associated with disease-free survival Factors associated with overall survival
Variable p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI)
Age 0.001 1.019 (1.008–1.031) <0.001 1.033 (1.017–1.051)
Sex 0.452 0.885 (0.643–1.217) 0.004 0.466 (0.276–0.784)
Ulceration <0.001 0.430 (0.306–0.604) 0.016 0.537 (0.325–0.889)
Positive SLNB <0.001 0.310 (0.220–0.435) <0.001 0.295 (0.180–0.483)
Breslow thickness <0.001 1.098 (1.072–1.124) <0.001 1.080 (1.049–1.111)
CI = confidence interval; SLNB = sentinel lymph node biopsy
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and SLNB result significantly affected overall survival;
previous reports have concluded that the overall survival of
patients with thick melanoma was affected by SLNB status
[26–28], ulceration [27, 28], and increased Breslow’s thick-
ness [12, 26, 28].
Thin melanoma
The overall incidence of a positive SLNB in thin melanoma
in prior studies has ranged from 0 to 7.8% but the studies
differed in their definition of thin melanoma and inclusion
criteria [25, 30–35]. Similarly, positive SLNB was detected
in 5.0% of our patients. Some authors have suggested that
SLNB is not useful unless it can be shown to improve sur-
vival, because thin primary melanoma has a 96% survival
rate after 20 years of follow-up [36, 37]. However, other
authors demonstrated sentinel node metastases as the single
most important prognostic indicator in patients with melan-
oma [36, 38, 39]. Of the patients with thin melanoma, 10
(2.2%) with locoregional recurrence and 15 (3.2%) with
distant metastases were observed, and there were signific-
antly more among the patients with positive SLNB (p =
0.007 and p = 0.003, respectively). Furthermore, Kaplan-
Meier methods interestingly showed that the patients with
negative SLNB had better disease-free survival than the pa-
tients with positive SLNB (p <0.001).
Our findings provide support for previous analyses [25, 39,
40], which showed that disease-free survival is signific-
antly associated with SLNB results in patients with thin
melanomas. Nevertheless, Wong et al. [41] did not find a
significant difference between thin melanomas with posit-
ive and negative sentinel lymph nodes regarding disease-
specific survival (p = 0.77). Although mean overall surviv-
al time in the patients with positive SLNB was less than the
patients with negative SLNB, this difference was not stat-
istically significant (p = 0.077) in our study. However, in
the recent studies, the importance of sentinel node status
in overall survival of melanoma patients was supported,
since thin melanomas with positive SLNB had significantly
poorer prognosis [25, 39, 40, 42].
Intermediate melanoma
The incidence of a positive SLNB in the intermediate
melanoma group in the current study was 19.3%. However,
Morton et al. found 16.0% tumour-positive sentinel nodes
in intermediate melanomas [43]. Our literature review
showed that SLNB in intermediate melanoma is less con-
troversial, because the staging of intermediate-thickness
primary melanomas according to the results of sentinel
node biopsy provides important prognostic information and
identifies patients with nodal metastases whose survival
can be prolonged by immediate lymphadenectomy. There-
fore, SLNB is recommended for patients with intermediate-
thickness melanomas of any anatomic site [43]. Locore-
gional recurrence, distant metastases and death attributed
to melanoma were detected in 26.3%, 29.5% and 20%, re-
spectively, of patients with intermediate melanomas and
positive SLNB, and were significantly different from the
patients with negative SLNB. (p<0.001). In contrast, Mor-
ton et al. reported a 26.2% melanoma-specific mortality
rate in the biopsy group if the node contained metastases
[43], which might be due to the thicker mean Breslow’s
depth in their groups compared with our patients (1.98 ±
0.63 mm vs 1.92 ± 2.70 mm). A significant difference
between sentinel node negative and node positive groups
was also observed in our study for disease-free and overall
survival (p <0.001). This observation is consistent with pri-
or reports of intermediate melanoma patients by Morton
et al., which showed significantly shorter disease-free and
overall survival in their patients with intermediate melano-
mas if the sentinel node was free of metastases (p <0.001)
[43].
Table 3: The association between sentinel lymph node biopsy result and clinical outcomes in patients with melanomas of different thickness.
Thin melanoma Intermediate melanoma Thick melanoma
Variable Negative
SLNB
Positive SLNB p-value Negative
SLNB
Positive SLNB p-value Negative
SLNB
Positive SLNB p-value
Locoregional
recurrence
(no./%)
6 (2.3) 3 (21.4) 0.007 40 (10.0) 25 (26.3) <0.001 16 (21.6) 24 (51.1) 0.001
Distant
metastases
(no./%)
4 (1.5) 3 (21.4) 0.003 36 (9.0) 28 (29.5) <0.001 18 (24.3) 22 (46.8) 0.017
Death
attributed to
melanoma
(no./%)
3 (1.1) 1 (7.1) 0.187 27 (6.7) 19 (20.0) <0.001 13 (17.6) 16 (34.0) 0.05
Table 4: The association between sentinel lymph node biopsy (SLNB) result and clinical outcomes in patients with different melanoma thicknesses.
Mean disease-free survival (years) Mean overall survival (years)
95% confidence interval 95% confidence interval
Melanoma
thickness
group
SLNB result
Estimate Std. error
Lower bound Upper bound
Estimate Std. error
Lower bound Upper bound
Negative 23.03 0.29 22.47 23.59 23.45 0.20 23.06 23.84Thin
Positive 8.62 1.50 5.68 11.57 11.92 0.91 10.14 13.71
Negative 15.73 0.49 14.77 16.68 17.84 0.45 16.96 18.73Intermediate
Positive 10.46 0.86 8.77 12.15 13.68 0.85 12.01 15.34
Negative 9.80 0.95 7.93 11.67 12.91 0.82 11.30 14.52Thick
Positive 6.20 1.04 4.15 8.25 10.10 0.99 8.16 12.03
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Thick melanoma
Positive SLNB was observed in 38.8% of the patients with
thick melanoma in the current study. Despite the fact that
SLNB for lymph node staging of thick primary cutaneous
melanomas has been recommended by various guideline
and studies [17, 29, 44–48], its beneficial effects are still
controversial [11, 26, 44]. Opponents state that the pro-
cedure is useless in the patients with thick melanoma be-
cause it does not provide significant prognostic informa-
tion, and outcome will be changed by occult metastasis
and not SLNB status [10, 26, 44, 49, 50]. These statements
have been supported by studies showing no benefit in over-
all survival according to the SLNB result [10, 11, 51]. On
the other hand, other evidence indicates that patients with
thick melanoma are not a homogenous group regarding
prognosis and tumour behaviour. Those with regional node
involvement may belong to a subgroup of thick melanoma
patients with a significantly worse prognosis than those
with negative SLNB [10, 26, 29, 52]. Evaluation of patients
with thick melanomas in the current study showed 51.1%
locoregional recurrence, 46.8% distant metastases and 34%
death attributed to melanoma, which were significantly
more frequent in the patients with positive SLNB (p =
0.001, p = 0.017 and p = 0.05, respectively). Likewise,
Fairbairn et al. found a 50% disease recurrence rate in pa-
tients with positive SLNB compared with 23% in those
with negative results [10]. Jacobs et al. found 8% disease
recurrence in the patients with a negative SLNB and 40%
recurrence in the SLNB positive group [29]. Furthermore,
survival analysis showed significantly better disease-free
survival in the patients with negative SLNB than in the
patients with positive SLNB (p = 0.008). Our findings
provide support for the previous analyses by Rughani et al.
[53], Gajdos et al. [26], Fujisawa et al. [12], Mozzillo [40]
and Fairbairn et al. [10], which showed that SLNB negative
thick melanomas were associated with a significantly better
disease-free survival. However, despite worse mean overall
survival of the patients with positive SLNB than of the pa-
tients with negative SLNB, this difference was not statist-
ically significant (p = 0.13). In a similar study, Fairbairn et
al. [10] did not find a significant difference in overall sur-
vival between the SLNB positive and negative groups (p =
0.66). On the other hand, Gershenwald et al. [27], Gajdos et
al. [26], Ferrone et al. [54], Carlson et al. [52], Rughani et
al. [53], Fujisawa et al. [12] and Mozzillo et al. [40] repor-
ted that overall survival differed significantly for the SLNB
positive patients compared with the SLNB negative group.
Limitations
Our current study is certainly not without limitations. The
chief of them was the study design – a retrospective obser-
vational study – and all the biases associated with this kind
of study should be taken into consideration. Furthermore,
we were not able to assess concerns about the morbidities
and complication rates following SLNB for our melanoma
patients.
Conclusion
The information obtained from the present study provides
insight into application of SLNB as a prognostic indicator
in patients with different thicknesses of melanoma. Based
on a recent phase III trial conducted by Morton et al. [38],
performing SLNB per se might not significantly change
10-year melanoma-specific survival, but it can signific-
antly prolong 10-year disease-free survival compared with
an observation group. Furthermore, biopsy-based staging
of melanomas provides important prognostic information,
and its outcome will inform the next steps in patient man-
agement, as it identifies patients with nodal metastases who
might benefit from immediate complete lymphadenectomy
or use of potential adjuvant therapies [38, 42, 55, 56].
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Figures (large format)
Figure 1
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free and overall survival in thin melanoma (p <0.001 and p = 0.077,
respectively).
Figure 2
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free and overall survival in intermediate melanoma (p <0.001 and p <0.001,
respectively).
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Figure 3
Effect of sentinel lymph node biopsy (SLNBx) result on disease-free and overall survival in thick melanoma (p = 0.008 and p = 0.13,
respectively).
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